PuSH - Publikationsserver des Helmholtz Zentrums München

Shahryari, A. ; Saghaeian Jazi, M.* ; Mohammadi, S.* ; Nikoo, H.R.* ; Nazari, Z.* ; Hosseini, E.S.* ; Burtscher, I. ; Mowla, S.J.* ; Lickert, H.

Development and clinical translation of approved gene therapy products for genetic disorders.

Front. Genet. 10:868 (2019)
Verlagsversion DOI
Open Access Gold
Creative Commons Lizenzvertrag
The field of gene therapy is striving more than ever to define a path to the clinic and the market. Twenty gene therapy products have already been approved and over two thousand human gene therapy clinical trials have been reported worldwide. These advances raise great hope to treat devastating rare and inherited diseases as well as incurable illnesses. Understanding of the precise pathomechanisms of diseases as well as the development of efficient and specific gene targeting and delivery tools are revolutionizing the global market. Currently, human cancers and monogenic disorders are indications number one. The elevated prevalence of genetic disorders and cancers, clear gene manipulation guidelines and increasing financial support for gene therapy in clinical trials are major trends. Gene therapy is presently starting to become commercially profitable as a number of gene and cell-based gene therapy products have entered the market and the clinic. This article reviews the history and development of twenty approved human gene and cell-based gene therapy products that have been approved up-to-now in clinic and markets of mainly North America, Europe and Asia.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Cell-based Gene Therapy ; Clinic ; Drug ; Gene Therapy ; Genetic Disease
ISSN (print) / ISBN 1664-8021
e-ISSN 1664-8021
Zeitschrift Frontiers in Genetics
Quellenangaben Band: 10, Heft: , Seiten: , Artikelnummer: 868 Supplement: ,
Verlag Frontiers
Begutachtungsstatus Peer reviewed